To evaluate the Safety and efficacy of Unani formulation in the treatment of Intestinal Worms
Phase 2
- Conditions
- Health Condition 1: null- DÄ«dÄ?n al-Amâ??Ä?â?? (Intestinal Worms)Health Condition 2: B820- Intestinal helminthiasis, unspecified
- Registration Number
- CTRI/2015/02/005544
- Lead Sponsor
- Central Council for Research in Unani Medicine CCRUM New Delhi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 300
Inclusion Criteria
•Patients of either sex in the age group of 10-60 years
•Patients of DÄ«dÄ?n al-Amâ??Ä?â?? (intestinal worms) with and without any of the following signs & symptoms:
ï??IkhrÄ?j-i-DÄ«dÄ?n (Passage of worms in stool)
ï??Wajaâ?? al-Batn Mutakarrar (Recurrent Abdominal Pain)
ï??Nafkh al-Batn (Abdominal Bloating)
ï??Hikka al-Maqâ??ad LaylÄ« (Nocturnal Perianal Itching)
ï??SarÄ«r al-AsnÄ?n (Odontoprisis)
ï??Kasrat-i-IfrÄ?z Luâ??Ä?b-i-Dahan (Water Brash especially in the morning hours)
Exclusion Criteria
•Known cases of cardiac, hepatic or renal ailments
•Patients having history of adverse reaction to any ingredient of the study drug.
•Patients on long-term medication
•Patients taking Vitamin C, B-Complex and Iron preparations
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement in signs and symptoms of DÄ«dÄ?n al-Amâ??Ä?â?? (Intestinal Worms)Timepoint: 2 weeks
- Secondary Outcome Measures
Name Time Method Haematological and biochemical assessment for safety assessmentTimepoint: 2 weeks